newsfilter
← Latest News
Business Wire·

Axcella Therapeutics Details Clinical and Operational Milestones for 2022

Long COVID Phase 2a top-line data anticipated in mid-2022 EMMPACT℠ Phase 2b interim data in nonalcoholic steatohepatitis (NASH) anticipated in mid-2022 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a